US biotech major Amgen (Nasdaq: AMGN) has announced financial results for the second quarter of 2023.
Revenue rose by 5.9% to $6.99 billion, above the FactSet consensus of $6.66 billion, while net income climbed to $1.38 billion, or $2.57 a share, from $1.32 billion, or $2.45 a share, in the same period a year ago.
Excluding non-recurring items, adjusted earnings per share of $5 beat the FactSet consensus of $4.49.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze